Replidyne Report issue

For profit Phase 3
Founded: Louisville CO United States (2000)
Status: Acquired by Cardiovascular Systems (2008) → now Abbott

Organization Overview

First Clinical Trial
2005
NCT00255983
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Replidyne, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

faropenem medoxomil (Fropenem) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 3)

Bronchitis (Phase 3)

Bronchitis, Chronic (Phase 3)

Otitis (Phase 2)

Otitis Media (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1